SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Compensation Committee of the Board of Directors (the “Board”) granted a stock-based award to a new employee, the company’s chief strategy officer, effective as of July 22, 2024, covering an aggregate of 115,000 shares of UNITY common stock, including options to purchase an aggregate of 100,000 shares of UNITY common stock and 15,000 Restricted Stock Units of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Media Contact
Inizio Evoke Comms
Katherine Smith
Katherine.Smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
Toronto, Ontario--(Newsfile Corp. - June 19, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE:…
SAN FRANCISCO, June 19, 2025 (GLOBE NEWSWIRE) -- Commure, the fast-growing enterprise AI healthcare technology…
New studies confirm the clear benefit of early acute treatment, the consistent effectiveness of REN…
MONTREAL, June 19, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“Cannara”, “the Company”, “us” or…
PRESS RELEASE Memo Therapeutics AG to Present Interim Phase II Results of Potravitug for the…
FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company…